Core Insights - Zacks Premium provides various tools for investors to enhance their stock market strategies and confidence [1][2] - The Zacks Style Scores are designed to help investors select stocks with the highest potential to outperform the market in the short term [3] Zacks Style Scores Overview - The Zacks Style Scores categorize stocks into four main types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [4][5][6][7] - Value Score identifies undervalued stocks using financial ratios [4] - Growth Score assesses stocks based on their future earnings and financial health [5] - Momentum Score tracks price trends to capitalize on upward or downward movements [6] - VGM Score combines all three styles to provide a comprehensive evaluation of stocks [7] Zacks Rank and Performance - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors [8] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41%, significantly outperforming the S&P 500 [9] - There are typically over 800 stocks rated 1 or 2, which can be overwhelming for investors [10] Stock Selection Strategy - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal investment potential [11] - The direction of earnings estimate revisions is crucial in stock selection, as lower-ranked stocks may still face declining forecasts [12][13] Company Spotlight: Zoetis Inc. - Zoetis Inc., established from Pfizer's animal health business spin-off, specializes in products for livestock and companion animals [14] - Currently rated 3 (Hold) with a VGM Score of B, Zoetis shows promise for growth investors with a projected earnings growth of 10.7% for the current fiscal year [15] - The company has seen upward revisions in earnings estimates, indicating positive market sentiment [15][16]

Zoetis Inc. (NYSE:ZTS) Jefferies London Healthcare Conference November 20, 2024 10:00 AM ET Company Participants Wetteny Joseph - CFO Conference Call Participants Glen Santangelo - Jefferies Glen Santangelo Thank you for taking the time to join us this afternoon. We're very excited to have Zoetis for our next presentation. For those of you who don't know me, I'm Glen Santangelo. I'm the analyst at Jefferies that covers the stock. I cover a number of things in addition to animal health, spec pharma and HCIT. ...

Summary of Zoetis Inc. Conference Call Company Overview - **Company**: Zoetis Inc. (NYSE: ZTS) - **Event**: Jefferies London Healthcare Conference - **Date**: November 20, 2024 - **Participants**: Wetteny Joseph (CFO), Glen Santangelo (Jefferies Analyst) Key Points Financial Performance - **Q3 Revenue Growth**: 14% operational growth in revenue, marking the third consecutive quarter of double-digit growth [2][3] - **Adjusted Net Income Growth**: 15% increase in adjusted net income [3] - **Companion Animal Segment**: Grew approximately 15%, with 8% from volume and 6% from price [5] - **Livestock Segment**: Achieved 11% growth in Q3, indicating strong performance despite broader market growth of 2% to 4% [36] Companion Animal Business - **Dermatology Franchise**: - Grew 16% in Q3, with Apoquel and Cytopoint driving growth [7][8] - Approximately 20 million dogs globally are under-treated for atopic dermatitis, presenting a significant market opportunity [8][10] - Increased awareness and direct-to-consumer campaigns have contributed to growth [8][10] - **Parasiticides**: - Trio product grew 30% year-over-year, with over half of the growth attributed to volume [14][15] - Significant market share gains from both new and existing customers [18] Market Dynamics - **Pricing Strategy**: - Price realization has improved, contributing to higher growth rates [20] - Excluding hyperinflationary impacts, the company expects to maintain pricing at or slightly above historical trends of 2% to 3% [6][41] - **Competition**: - Anticipated competition in dermatology and parasiticides is expected to drive market education and growth [10][13] Future Outlook - **Guidance for 2024**: - Revenue growth guidance raised to 10% to 11% from previous estimates [38] - Anticipated strong year-over-year growth in 2025, despite the impact of the MFA divestiture [41] - **Livestock Business**: - Expected to continue double-digit growth, with adjustments post-divestiture of the medicated feed additives business [36][37] Additional Insights - **Safety Profile**: Ongoing routine discussions with the FDA regarding product safety, with no unusual concerns reported [32][33] - **Market Trends**: Increasing pet ownership and the human-animal bond are driving demand for veterinary care and products [10][11] Conclusion Zoetis Inc. demonstrated robust financial performance in Q3 2024, with significant growth across its companion animal and livestock segments. The company is well-positioned for future growth, supported by strong market dynamics, effective pricing strategies, and ongoing product innovation.

Company Overview - Zoetis Inc. (NYSE: ZTS) is recognized as a global market leader in animal health products, demonstrating a trajectory of slow and steady growth for the foreseeable future [1]. Investment Philosophy - The investment approach emphasizes the importance of compounding, dividend reinvesting, and patient investing through various market conditions to achieve significant rewards [1]. - The strategy includes a mix of steady investments in high-quality assets along with high-risk/high-reward opportunities, underappreciated turnaround plays, and transformative technologies [1]. Personal Background of the Analyst - The analyst identifies as an amateur investor with over 25 years of experience, self-taught without formal education in investing or business, and values learning from others [1]. - The analyst holds a PhD from Brunel University and is also involved in teaching at the college/university level [1].

I upgraded Zoetis (NYSE: ZTS ) to a 'Buy' rating in August 2024, highlighting the company's direct-to-customer strategy and investment in new products. Zoetis delivered a strong growth in Q3 FY24, with 14% year-over-year growth in both revenue and adjusted net income. Notably, their companion animalMore than 15 years of professional investment experience in global equities across all sectors. My investment style is fundamental, bottom-up, long-term, and quality growth-oriented. I am seeking companies specia ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-35797 Zoetis Inc. (Exact name of registrant as specified in its charter) | --- | -- ...

Zoetis, Inc. (ZTS) delivered third-quarter 2024 adjusted earnings (excluding one-time items) of $1.58 per share, which surpassed the Zacks Consensus Estimate of $1.46 per share. In the year-ago quarter, the company delivered adjusted earnings of $1.36 per share. Total revenues grew 11% year over year to $2.39 billion in the reported quarter, which beat the Zacks Consensus Estimate of $2.29 billion. In the year-ago quarter, the company reported total revenues of $2.15 billion. Shares of Zoetis are gaining in ...

Zoetis Inc. (NYSE:ZTS) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Steve Frank - VP of IR Kristin Peck - CEO Wetteny Joseph - CFO Conference Call Participants Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Brandon Vazquez - William Blair Jon Block - Stifel David Westenberg - Piper Sandler Balaji Prasad - Barclays Glen Santangelo - Jefferies Chris Schott - JPMorgan Chris LoBianco - TD Cowen Navann Ty - BNP Paribas Operator Welcome to the Third Quarter 2024 ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team covers key finance and investing hubs, focusing on medium and small-cap markets, as well as blue-chip companies and broader investment stories [2][3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3][4] Group 2 - The company utilizes technology to enhance workflows and has a team with decades of expertise [3] - Proactive employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [4]

| --- | --- | --- | --- | --- | --- | --- | --- | |----------|-----------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Third | | | | | | | | | | Quarter | | | | | | | | 2024 | Financial | | | | | | | | November | 4, 2024 Results | | | | | | | | | | | | | | | | Forward-Looking Statements This presentation contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospect ...